154 related articles for article (PubMed ID: 16424004)
1. Profiling genetic variation along the androgen biosynthesis and metabolism pathways implicates several single nucleotide polymorphisms and their combinations as prostate cancer risk factors.
Mononen N; Seppälä EH; Duggal P; Autio V; Ikonen T; Ellonen P; Saharinen J; Saarela J; Vihinen M; Tammela TL; Kallioniemi O; Bailey-Wilson JE; Schleutker J
Cancer Res; 2006 Jan; 66(2):743-7. PubMed ID: 16424004
[TBL] [Abstract][Full Text] [Related]
2. Genetic polymorphisms of CYP17A1, vitamin D receptor and androgen receptor in Italian heredo-familial and sporadic prostate cancers.
Risio M; Venesio T; Kolomoets E; Armaroli P; Gallo F; Balsamo A; Muto G; D'Urso L; Puppo P; Naselli A; Segnan N;
Cancer Epidemiol; 2011 Aug; 35(4):e18-24. PubMed ID: 21094112
[TBL] [Abstract][Full Text] [Related]
3. Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways.
Latil AG; Azzouzi R; Cancel GS; Guillaume EC; Cochan-Priollet B; Berthon PL; Cussenot O
Cancer; 2001 Sep; 92(5):1130-7. PubMed ID: 11571725
[TBL] [Abstract][Full Text] [Related]
4. Association of the polymorphisms of genes involved in androgen metabolism and signaling pathways with familial prostate cancer risk in a Japanese population.
Okugi H; Nakazato H; Matsui H; Ohtake N; Nakata S; Suzuki K
Cancer Detect Prev; 2006; 30(3):262-8. PubMed ID: 16859836
[TBL] [Abstract][Full Text] [Related]
5. Effects of functional genetic polymorphisms in the CYP19A1 gene on prostate cancer risk and survival.
Kanda S; Tsuchiya N; Narita S; Inoue T; Huang M; Chiba S; Akihama S; Saito M; Numakura K; Tsuruta H; Satoh S; Saito S; Ohyama C; Arai Y; Ogawa O; Habuchi T
Int J Cancer; 2015 Jan; 136(1):74-82. PubMed ID: 24803183
[TBL] [Abstract][Full Text] [Related]
6. Association of androgen metabolism gene polymorphisms with prostate cancer risk and androgen concentrations: Results from the Prostate Cancer Prevention Trial.
Price DK; Chau CH; Till C; Goodman PJ; Leach RJ; Johnson-Pais TL; Hsing AW; Hoque A; Parnes HL; Schenk JM; Tangen CM; Thompson IM; Reichardt JK; Figg WD
Cancer; 2016 Aug; 122(15):2332-40. PubMed ID: 27164191
[TBL] [Abstract][Full Text] [Related]
7. Role of androgen metabolism genes CYP1B1, PSA/KLK3, and CYP11alpha in prostate cancer risk and aggressiveness.
Cicek MS; Liu X; Casey G; Witte JS
Cancer Epidemiol Biomarkers Prev; 2005 Sep; 14(9):2173-7. PubMed ID: 16172228
[TBL] [Abstract][Full Text] [Related]
8. Genetic polymorphisms of estrogen receptor alpha, CYP19, catechol-O-methyltransferase are associated with familial prostate carcinoma risk in a Japanese population.
Suzuki K; Nakazato H; Matsui H; Koike H; Okugi H; Kashiwagi B; Nishii M; Ohtake N; Nakata S; Ito K; Yamanaka H
Cancer; 2003 Oct; 98(7):1411-6. PubMed ID: 14508827
[TBL] [Abstract][Full Text] [Related]
9. Identifying susceptibility genes for prostate cancer--a family-based association study of polymorphisms in CYP17, CYP19, CYP11A1, and LH-beta.
Douglas JA; Zuhlke KA; Beebe-Dimmer J; Levin AM; Gruber SB; Wood DP; Cooney KA
Cancer Epidemiol Biomarkers Prev; 2005 Aug; 14(8):2035-9. PubMed ID: 16103457
[TBL] [Abstract][Full Text] [Related]
10. Variants in estrogen biosynthesis genes, sex steroid hormone levels, and endometrial cancer: a HuGE review.
Olson SH; Bandera EV; Orlow I
Am J Epidemiol; 2007 Feb; 165(3):235-45. PubMed ID: 17110639
[TBL] [Abstract][Full Text] [Related]
11. Association between cytochrome CYP17A1, CYP3A4, and CYP3A43 polymorphisms and prostate cancer risk and aggressiveness in a Korean study population.
Han JH; Lee YS; Kim HJ; Lee SY; Myung SC
Asian J Androl; 2015; 17(2):285-91. PubMed ID: 25337833
[TBL] [Abstract][Full Text] [Related]
12. Germ-line genetic variation in the key androgen-regulating genes androgen receptor, cytochrome P450, and steroid-5-alpha-reductase type 2 is important for prostate cancer development.
Lindström S; Wiklund F; Adami HO; Bälter KA; Adolfsson J; Grönberg H
Cancer Res; 2006 Nov; 66(22):11077-83. PubMed ID: 17108148
[TBL] [Abstract][Full Text] [Related]
13. CYP17 polymorphisms in relation to risks of prostate cancer and benign prostatic hyperplasia: a population-based study in China.
Madigan MP; Gao YT; Deng J; Pfeiffer RM; Chang BL; Zheng S; Meyers DA; Stanczyk FZ; Xu J; Hsing AW
Int J Cancer; 2003 Nov; 107(2):271-5. PubMed ID: 12949806
[TBL] [Abstract][Full Text] [Related]
14. Combination of polymorphisms from genes related to estrogen metabolism and risk of prostate cancers: the hidden face of estrogens.
Cussenot O; Azzouzi AR; Nicolaiew N; Fromont G; Mangin P; Cormier L; Fournier G; Valeri A; Larre S; Thibault F; Giordanella JP; Pouchard M; Zheng Y; Hamdy FC; Cox A; Cancel-Tassin G
J Clin Oncol; 2007 Aug; 25(24):3596-602. PubMed ID: 17704407
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer associated with CYP17 genotype.
Wadelius M; Andersson AO; Johansson JE; Wadelius C; Rane E
Pharmacogenetics; 1999 Oct; 9(5):635-9. PubMed ID: 10591544
[TBL] [Abstract][Full Text] [Related]
16. Associations between polymorphisms in genes related to estrogen metabolism and function and prostate cancer risk: results from the Prostate Cancer Prevention Trial.
Tang L; Platek ME; Yao S; Till C; Goodman PJ; Tangen CM; Wu Y; Platz EA; Neuhouser ML; Stanczyk FZ; Reichardt JKV; Santella RM; Hsing A; Figg WD; Lippman SM; Thompson IM; Ambrosone CB
Carcinogenesis; 2018 Feb; 39(2):125-133. PubMed ID: 29228205
[TBL] [Abstract][Full Text] [Related]
17. [Polymorphisms of hormone-related genes and prostate cancer risk in Japan].
Watanabe M; Hirokawa Y; Shiraishi T
Nihon Rinsho; 2005 Feb; 63(2):219-24. PubMed ID: 15714969
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of genetic variations in the androgen and estrogen metabolic pathways as risk factors for sporadic and familial prostate cancer.
Cunningham JM; Hebbring SJ; McDonnell SK; Cicek MS; Christensen GB; Wang L; Jacobsen SJ; Cerhan JR; Blute ML; Schaid DJ; Thibodeau SN
Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):969-78. PubMed ID: 17507624
[TBL] [Abstract][Full Text] [Related]
19. Allelic variants of aromatase and the androgen and estrogen receptors: toward a multigenic model of prostate cancer risk.
Modugno F; Weissfeld JL; Trump DL; Zmuda JM; Shea P; Cauley JA; Ferrell RE
Clin Cancer Res; 2001 Oct; 7(10):3092-6. PubMed ID: 11595700
[TBL] [Abstract][Full Text] [Related]
20. Association of prostate cancer risk and aggressiveness to androgen pathway genes: SRD5A2, CYP17, and the AR.
Cicek MS; Conti DV; Curran A; Neville PJ; Paris PL; Casey G; Witte JS
Prostate; 2004 Apr; 59(1):69-76. PubMed ID: 14991867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
